Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.57 Consensus Price Target from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $16.5714.

Several research firms have recently issued reports on FOLD. JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group raised their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 1st.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $9.85 on Friday. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of -246.19 and a beta of 0.46. The firm’s fifty day simple moving average is $8.98 and its 200-day simple moving average is $7.55. Amicus Therapeutics has a twelve month low of $5.51 and a twelve month high of $10.57. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company’s revenue was up 19.5% compared to the same quarter last year. Equities analysts forecast that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In related news, insider Jeff Castelli sold 76,158 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider owned 439,318 shares in the company, valued at $4,463,470.88. This trade represents a 14.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Michael Clark sold 25,643 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total value of $243,864.93. Following the transaction, the insider directly owned 322,618 shares in the company, valued at approximately $3,068,097.18. This trade represents a 7.36% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 216,239 shares of company stock worth $2,165,304. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds have recently modified their holdings of FOLD. Allworth Financial LP raised its position in Amicus Therapeutics by 36.3% in the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,246 shares during the last quarter. Swiss Life Asset Management Ltd acquired a new position in Amicus Therapeutics in the third quarter valued at $83,000. CIBC Bancorp USA Inc. acquired a new position in Amicus Therapeutics in the third quarter valued at $234,000. Sender Co & Partners Inc. acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $272,000. Finally, PharVision Advisers LLC purchased a new position in shares of Amicus Therapeutics during the third quarter worth about $95,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.